Stock Taper
SCREENER COMPARE ANY 2 STOCKS
AMGN
AMGEN INC.
NASDAQ
$429.88
▼ DOWN 0.59% (-2.54)

KEY STATISTICS

Market Cap$232.72 B
52w High$447.03
52w Low$269.77
Dividend Yield2.58%
FrequencyQuarterly
P/E19.22
Volume2.31M
Shares Out.539.71M

COMPANY

LEADERSHIP

Robert A. Bradway
CHIEF EXECUTIVE
Robert A. Bradway

COMPENSATION 2026

Salary$1,925,409
Stock Awards$12,599,589
Incentive Plan Pay$3,907,000
All Other Comp.$861,126
Total$24,693,120

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 17, 1983
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
31,500

PRICE TARGET

Target High$460.00
Target Low$230.00
Target Median$388.00
Target Consensus$386.68

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$10.05B
NOV
3
TUE

SPLIT RECORD

DATETYPERATIO
1999-11-22Forward2:1
1999-03-01Forward2:1
1995-08-16Forward2:1
1991-09-11Forward3:1
1990-08-13Forward2:1

PRICE

$429.88 ▼ DOWN 0.59% (−$2.54)
OVERLAYS
$428$429$431$4329:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM429.88

About Amgen Inc.

https://www.amgen.com ↗

Amgen Inc. is a global biotech company that develops and markets human therapeutics across areas like oncology, inflammation, and cardiovascular disease, partnering with various firms to innovate and distribute a broad portfolio of medicines.

INDUSTRY

Drug Manufacturers - General

A PRODUCT AMGEN INC. IS KNOWN FOR

Uplizna® (inebilizumab)
Uplizna® (inebilizumab)

Uplizna, a monoclonal antibody approved in 2025-2026 for generalized myasthenia gravis, marks a significant advancement in autoimmune treatment and reflects Amgen's focus on inflammation and rare diseases.

COMPETITORS

COMPETITOR
ARGX COMPARE
AZN COMPARE
BIIB COMPARE
NVS COMPARE
ROG COMPARE

Revenue by Products

IconPRODUCTQ2-2025Q3-2025Q4-2025Q2-2026
Other products$1.69B $1.85B ▲$2.07B ▲$1.7B ▼
Repatha— — — $953M
Repatha evolocumab$696M $794M ▲— —
Prolia$1.12B $1.14B ▲$1.05B ▼$759M ▼
EVENITY$518M $541M ▲$599M ▲$714M ▲
ENBREL$604M $580M ▼$532M ▼$580M ▲
TEPEZZA$505M $560M ▲$457M ▼$576M ▲
Other revenues— — — $517M
Product and Service Other$408M $420M ▲$499M ▲—
Otezla$618M $585M ▼$625M ▲$491M ▼
TEZSPIRE$342M $377M ▲$474M ▲$486M ▲
BLINCYTO$384M $392M ▲$413M ▲$472M ▲
Nplate$369M $457M ▲$385M ▼$430M ▲
KRYSTEXXA$349M $320M ▼$435M ▲$400M ▼
Aranesp$359M $357M ▼$333M ▼$352M ▲
XGEVA$532M $539M ▲$447M ▼$352M ▼
Vectibix$305M $284M ▼$319M ▲$338M ▲
UPLIZNA— — — $335M
KYPROLIS$378M $359M ▼— $314M ▼
IMDELLTRAIMDYLLTRA— — — $288M

Revenue by Geography

MapREGIONQ2-2025Q3-2025Q4-2025Q2-2026
UNITED STATES$6.32B $6.75B ▲$7.68B ▲$6.99B ▼
NonUS$2.45B $2.39B ▼$3.29B ▲$2.55B ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
1,207
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.29% · 17.2M
SCHD
4.79% · 12.2M
QQQ
1.03% · 11.6M
IVV.AX
0.35% · 7.2M
SPY
0.35% · 6.6M
FLCB
0.09% · 2.9M
DIVO
5.20% · 955.6K
CGDV
0.99% · 882.1K
DUHP
1.56% · 456.5K
FTCS
2.26% · 415.8K
JEPQ
0.42% · 404.2K
QQQI
1.03% · 338.8K
TQQQ
0.39% · 326.5K
FHLC
3.22% · 258.7K
XDWH.DE
2.74% · 257.2K
LYP2.DE
0.27% · 203.0K
QYLD
1.05% · 202.0K
DLN
1.21% · 177.8K
WSRUS.SW
1.06% · 172.5K
BBH
15.45% · 170.0K
ZSP.TO
0.35% · 167.8K
NDQ.AX
1.03% · 151.8K
GPIQ
0.97% · 124.7K
PB
PBPH
4.93% · 117.0K
H4ZJ.SG
0.25% · 110.7K
AFTY
5.17% · 88.6K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
60.85%
HOLDERS
4,181
TOP 12 OF 4,181 · RANKED BY POSITION SIZE
Vanguard Group Inc
54.8M sh · $17.95B
Blackrock, Inc.
49.4M sh · $17.87B
Blackrock Inc.
46.0M sh · $14.39B
State Street Corp
30.6M sh · $10.01B
Capital World Investors
29.3M sh · $10.3B
Blackrock Institutional Trust Company, N.A.
21.1M sh · $3.08B
Capital International Investors
19.2M sh · $5.41B
Invesco Ltd.
16.3M sh · $5.91B
Morgan Stanley
15.9M sh · $4.49B
Geode Capital Management, LLC
15.7M sh · $5.67B
Charles Schwab Investment Management Inc
15.0M sh · $5.44B
Sixth Street Partners Management Company, L.P.
15.0M sh · $5.44B

RATINGS SNAPSHOT

Overall rating: B+

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity5
Return On Assets5
Debt To Equity1
Price To Earnings2
Price To Book1
Overall Score3

TRADES BY CONGRESS

HOUSE TRADES
Maria Elvira Salazar
Maria Elvira Salazar
Sale
2026-04-17
SENATE TRADES
Mark Warner
Mark Warner
Sale
2026-04-07
HOUSE TRADES
David Taylor
David Taylor
Sale
2026-02-26
 Marjorie Taylor Greene
Marjorie Taylor Greene
Purchase
2025-10-24

INSIDER TRADES

★
OFFICER: SVP, BUSINESS DEVELOPMENT
Khosla Rachna
Sale · 2.0K shares
2026-08-11
★
OFFICER: SVP, BUSINESS DEVELOPMENT
Khosla Rachna
Sale · 1.3K shares
2026-08-13
★
OFFICER: SVP, BUSINESS DEVELOPMENT
Khosla Rachna
Purchase · 1.3K shares
2026-08-13
★
OFFICER: VP, FINANCE & CAO
Busch Matthew C.
Purchase · 730 shares
2026-08-07

MOST RECENT ANALYST GRADES

GRADE SUMMARY
NEUTRAL 4
OUTPERFORM 4
BUY 3
EQUAL WEIGHT 3
HOLD 2
OVERWEIGHT 1
MARKET PERFORM 1
SECTOR OUTPERFORM 1
UNDERPERFORM 1
20 GRADES IN THE LAST 12 MONTHS
Piper Sandler OVERWEIGHT Argus Research BUY Mizuho NEUTRAL Cantor Fitzgerald NEUTRAL Barclays EQUAL WEIGHT Guggenheim NEUTRAL Citigroup NEUTRAL Bernstein MARKET PERFORM

SECTORS PEERS

PEERPRICE
MRK$147.97COMPARE
NVS$152.21COMPARE
NVO$45.47COMPARE
GILD$146.44COMPARE
PFE$28.59COMPARE
DHR$214.65COMPARE
BMY$66.64COMPARE
SNY$44.51COMPARE